Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on NewAmsterdam Pharma NAMS in the last three months.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $40.88, a high estimate of $48.00, and a low estimate of $36.00. Marking an increase of 7.18%, the current average surpasses the previous average price target of $38.14.

Diving into Analyst Ratings: An In-Depth Exploration

The analysis of recent analyst actions sheds light on the perception of NewAmsterdam Pharma by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NewAmsterdam Pharma. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NewAmsterdam Pharma compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NewAmsterdam Pharma's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NewAmsterdam Pharma's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on NewAmsterdam Pharma analyst ratings.

Unveiling the Story Behind NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma: A Financial Overview

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: NewAmsterdam Pharma's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 889.83%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: NewAmsterdam Pharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -57.18%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): NewAmsterdam Pharma's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -4.34%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.76%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: NewAmsterdam Pharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.

The Basics of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.